dQ&A's latest diabetes research includes two presentations from our team at ATTD 2026, one of the world's leading stages for diabetes advancements.
Our quarterly U.S. survey shows diabetes sharply reduces productivity and daily-life capacity—evidence that employers must offer stronger support.
Our quarterly U.S. diabetes survey found one-third of respondents had mild or severe depression, underscoring the need for more support and better treatments.
Erik Shoger presented real-world patient insights at the FDA advisory meeting on sotagliflozin, highlighting the need for education and training if approved.
